Elk Creek Partners’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Elk Creek Partners’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$5.36M	Buy	751,138 +286,732	+62%	+$3.58M	0.92%	44
2019 Q4	$11.1M	Buy	464,406 +33,581	+8%	+$926K	1.28%	24
2019 Q3	$11.6M	Buy	430,825 +13,236	+3%	+$372K	0.99%	41
2019 Q2	$11.3M	Buy	417,589 +15,322	+4%	+$480K	0.85%	47
2019 Q1	$14M	Buy	402,267 +24,462	+6%	+$706K	1.01%	32
2018 Q4	$7.38M	Buy	+377,805	New	+$7.77M	0.61%	68

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Elk Creek Partners's PTLA Position: Q1 2020 in Review

Elk Creek Partners increased its Portola Pharmaceuticals, Inc. (PTLA) stake by 62% in Q1 2020, buying an estimated $3.58M and bringing the position to 751,138 shares worth $5.36M. The position accounts for 0.92% of the portfolio, ranked #44.

Elk Creek Partners first reported a position in PTLA in Q4 2018 and has held it in 6 quarters since. The position peaked at $14M in Q1 2019. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

Elk Creek Partners held 751,138 shares of Portola Pharmaceuticals, Inc. worth $5.36M as of Q1 2020.
Elk Creek Partners bought 286,732 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $3.58M.
Portola Pharmaceuticals, Inc. made up 0.92% of Elk Creek Partners's portfolio in Q1 2020, its #44 holding.
Elk Creek Partners first reported a position in Portola Pharmaceuticals, Inc. in Q4 2018 and has held it in 6 quarters since.
Elk Creek Partners's Portola Pharmaceuticals, Inc. position peaked at $14M in Q1 2019.
187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Elk Creek Partners's 13F filing for Q1 2020, filed 14 May 2020.